Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
Elena StrekalovaDmitry MalinHarisha RajanalaVincent L CrynsPublished in: Breast cancer research and treatment (2017)
Our findings indicate that metformin enhances the activity of TRAIL receptor agonists, thereby supporting the rationale for additional translational studies combining these agents.